Market Cap: $434.5M
RI
REGENXBIO Inc.
RGNX
NASDAQ (NASDAQ Global Select)USD
Market Cap: $434.5M
Regenxbio (Ticker: RGNX) is making significant strides in the field of gene therapy with its recent alignment with the U.S. Food and Drug Administration (FDA) concerning the potential accelerated appr…
REGENXBIO Inc. (Ticker: RGNX) has made significant strides in the development of its gene therapy RGX-202 for Duchenne Muscular Dystrophy (DMD), as demonstrated by the recent results from its pivotal…
REGENXBIO Inc. is set to highlight its advancements in gene therapy at the upcoming 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place from May 11-15 in Boston, Massachu…
Dr. Pakola's Legal Woes Spotlight Safety Concerns in Gene Therapy Dr. Stephen Pakola, M.D., currently serving as the Executive Vice President and Chief Medical Officer at REGENXBIO, faces a securities…
Legal Challenges Loom for Regenxbio Over RGX-111 Assertions Regenxbio Inc., a biotechnology company specializing in gene therapy, faces significant legal challenges stemming from class action lawsuits…
Regenxbio Faces Legal Scrutiny Over Alleged Misleading Claims About Gene Therapy RGX-111 Regenxbio, Inc., a biotech firm focused on gene therapy innovations, finds itself at the center of a securities…
### Accountability in Gene Therapy: REGENXBIO's Legal Challenges REGENXBIO, a biotechnology company focused on gene therapy, faces serious legal repercussions following allegations of misleading inves…
Rosen Law Firm Reminds Investors of Lead Plaintiff Deadline in REGENXBIO Securities Class Action Rosen Law Firm is alerting investors who purchased REGENXBIO, Inc. (NASDAQ: RGNX) securities between Fe…
Regenxbio's Legal Challenges Center on Gene Therapy Safety Claims Regenxbio, a leading biotechnology company specializing in gene therapy, is currently embroiled in a securities class action lawsuit t…
### REGENXBIO Faces Class Action Lawsuit Over RGX-111 Misrepresentations REGENXBIO Inc. is embroiled in a class action securities lawsuit initiated by Levi & Korsinsky, LLP, targeting the gene therapy…
Title: REGENXBIO Faces Legal Challenges Amid Concerns Over RGX-111 Gene Therapy REGENXBIO Inc., a prominent player in the gene therapy sector, finds itself navigating turbulent waters as legal scrutin…
Regulatory Challenges Ahead for the Biopharmaceutical Sector Following CBER Leader's Departure The impending departure of Dr. Vinay Prasad as head of the FDA's Center for Biologics Evaluation and Rese…
Regenxbio Faces Class Action Lawsuit Over RGX-111 Allegations REGENXBIO, Inc. finds itself at the center of a class action lawsuit triggered by allegations of misleading statements related to its gene…
Title: Regenxbio Navigates Regulatory Uncertainty Amid Stiff Challenges for Gene Therapy Approvals In the current biopharmaceutical landscape, Regenxbio faces significant hurdles as regulatory scrutin…
### REGENXBIO Propels Forward Despite Setbacks in Gene Therapy Development REGENXBIO, Inc. (NASDAQ: RGNX) demonstrates resilience in the gene therapy landscape, as evidenced by its fourth-quarter earn…
Regulatory Hurdles Impede REGENXBIO's RGX-111 Gene Therapy Development REGENXBIO Inc., a biopharmaceutical company recognized for pioneering gene therapy solutions, finds itself at a crossroads follow…
Regenxbio Faces Class Action Lawsuit Over RGX-111 Safety Concerns Regenxbio is currently facing legal challenges as Robbins LLP files a class action lawsuit on behalf of investors who acquired shares…
Regenxbio Faces Class Action Lawsuit Amidst Controversy Over RGX-111 Regenxbio, a biopharmaceutical company known for its pioneering gene therapies, is currently embroiled in a class action lawsuit fi…
REGENXBIO Faces Legal Scrutiny Over Gene Therapy Safety Concerns REGENXBIO Inc. is currently under investigation by Faruqi & Faruqi, LLP, a prominent securities law firm, for potential claims regardin…
Regenxbio Faces Class Action Lawsuits Over RGX-111 Misrepresentation Claims Regenxbio Inc. stands at the center of multiple class action lawsuits involving accusations of misleading investors regardin…
Regulatory Challenges Shadow REGENXBIO’s Gene Therapy Aspirations REGENXBIO Inc. faces significant legal scrutiny following a class action securities lawsuit launched by Levi & Korsinsky, LLP. The law…
Regenxbio Faces Legal Scrutiny Over Gene Therapy Promises Regenxbio Inc. finds itself at the center of multiple class action lawsuits due to allegations surrounding its gene therapy candidate, RGX-111…
Regenxbio Faces Class Action Lawsuits Over Misleading Product Claims Regenxbio Inc., a biotechnology company known for its innovative gene therapy products, is currently confronting significant legal…
### RGX-111 Under Fire: Allegations of Misleading Safety and Efficacy Claims Regenxbio Inc. faces significant legal challenges related to its lead product candidate, RGX-111. A class action lawsuit, f…
Regenxbio Faces Legal Challenges Over RGX-111 Safety Claims Regenxbio Inc. is embroiled in a class action lawsuit initiated by the Schall Law Firm, which highlights significant allegations regarding m…